ÂÜÀòÂÒÂ×

Anker Lundemose serves as the Chief Executive Officer of MISSION Therapeutics Ltd, a position held since January 2015, and possesses extensive experience in business and corporate development as well as R&D across therapeutic areas including oncology, diabetes, and anti-infectives. Lundemose is currently a Non Executive Director at Isomab Ltd, and the Non Executive Chairman of ComMIT Biologics, having also held the Chairman role at InThera Bioscience AG until January 2024. Previous non-executive positions include roles at Macrophage Pharma, Antag Therapeutics, Abzena plc, and Saniona AB. Lundemose is also the Owner & Managing Partner of BioTesch Advice and has served on the Board of Directors for Adenium Biotech. Anker Lundemose obtained an MD PhD DMSc in Medicine from Aarhus University between 1980 and 1988.